Enjaymo

CAD | Enjaymo Not Cost-Effective at Current Price, According to US Study

This conclusion was drawn from a cost-effectiveness study utilizing data from the Phase 3 CARDINAL clinical trial, which backed the treatment’s approval for CAD patients with a recent history of…

Read More »

COLD AGGLUTININ DISEASE | Enjaymo Improved Life Quality in Patients for 2.5 Years

“Enjaymo provides sustained and durable treatment benefits in chronic CAD, including a continued meaningful impact on patient quality of life in the long term,” the researchers wrote. However, these benefits…

Read More »